Therapy-related myelodysplastic syndrome with monosomy 5 and 7 following successful therapy for acute promyelocytic leukemia with anthracyclines.
Myelodysplastic syndrome (MDS) in patients treated for acute promyelocytic leukemia (APL) is a rare event. We describe a patient with APL who developed MDS 40 months after entering complete remission (CR). Karyotypic analysis revealed monosomy 5 and 7, which are cytogenetic changes usually occurring after the use of alkylating agents. The patient had received only anthracyclines as potential leukemogenic drugs. A review of the literature on t-AML/MDS occurring after successful therapy for APL showed three similar cases. These observations suggest that anthracyclines may cause t-AML/MDS similar to that induced by alkylating agents.
Athanasiadou
A
A
Department of Haematology, "George Papanicolaou" General Hospital, 57010 Exokhi, Thessaloniki, Greece.
Saloum
R
R
Zorbas
I
I
Tsompanakou
A
A
Batsis
I
I
Fassas
A
A
Anagnostopoulos
A
A
D000903:Antibiotics, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D002895:Chromosomes, Human, Pair 5; D002897:Chromosomes, Human, Pair 7; D017809:Fatal Outcome; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy; D006801:Humans; D007165:Immunosuppression Therapy; D015470:Leukemia, Myeloid, Acute / Q000209:etiology; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000628:therapy; D008875:Middle Aged; D009006:Monosomy; D009190:Myelodysplastic Syndromes / Q000139:chemically induced* / Q000235:genetics / Q000473:pathology; D016609:Neoplasms, Second Primary / Q000139:chemically induced* / Q000235:genetics / Q000473:pathology; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects; D014184:Transplantation, Homologous
D000903:Antibiotics, Antineoplastic